Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resten-MP with Bare Metal Stent in de novo Native Coronary Artery Lesions
2005-000713-35Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Dec 2005
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of avi-4126 in coronary stenosis, sponsored by Sarepta Therapeutics. Primary endpoint: In-stent late lumen loss at Month 6. Started Dec 2005; status: completed.
02
Drugs
avi-4126
03
Conditions
coronary stenosis
Beyond the preview
Go deeper on 2005-000713-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000713-35.